Eloxx Pharmaceuticals, Inc. (ELOX) stock
ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$11.74−1.01 (-7.92%)
Close on Nov 17, 2026Market cap $79.70MP/E –Yield –
Eloxx Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Eloxx Pharmaceuticals's R&D Expenses for the twelve months ending Dec 31, 2023 was $8.60M, down 63.8% year over year. For fiscal 2025 it was $3.06M, down 14.6% from the year before. Over ten years it grew -0.9% a year on average. The highest annual figure on record is $26.35M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.06M | -14.6% |
| FY2024 | Dec 31, 2024 | $3.58M | -58.4% |
| FY2023 | Dec 31, 2023 | $8.60M | -63.8% |
| FY2022 | Dec 31, 2022 | $23.73M | +3.6% |
| FY2021 | Dec 31, 2021 | $22.90M | +56.9% |
| FY2020 | Dec 31, 2020 | $14.59M | -44.6% |
| FY2019 | Dec 31, 2019 | $26.35M | +28.6% |
| FY2018 | Dec 31, 2018 | $20.49M | +838.6% |
| FY2016 | Jun 30, 2016 | $2.18M | -52.2% |
| FY2015 | Jun 30, 2015 | $4.57M | +36.8% |
| FY2014 | Jun 30, 2014 | $3.34M | +60.0% |
| FY2013 | Jun 30, 2013 | $2.09M | -18.7% |
| FY2012 | Jun 30, 2012 | $2.57M | -31.0% |
| FY2011 | Jun 30, 2011 | $3.72M | +41.1% |
| FY2010 | Jun 30, 2010 | $2.64M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $2.84M | +86.6% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $1.66M | +32.7% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $898.00K | -61.6% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $510.00K | -85.4% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $1.52M | -53.8% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $1.25M | -74.4% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $2.34M | -69.4% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $3.49M | -55.8% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $3.30M | -58.3% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $4.88M | -6.3% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $7.65M | +34.1% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $7.90M | +93.9% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $7.91M | +194.1% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $5.21M | +53.2% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $5.70M | +54.2% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $4.07M | -14.6% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $2.69M | -56.5% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $3.40M | -50.0% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $3.70M | -49.6% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $4.77M | -20.8% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $6.19M | -5.2% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $6.80M | +25.6% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $7.34M | +76.9% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $6.02M | +37.0% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $6.53M | +1490.9% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $5.42M | +839.4% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $4.15M | +598.1% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $4.39M | +630.4% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $410.46K | -51.2% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $576.44K | +145.0% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $594.50K | -56.7% |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $601.58K | -71.6% |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $841.09K | +1.3% |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $235.26K | -75.7% |
| Q2 FY2015CQ4 2014 | Dec 31, 2014 | $1.37M | – |
| Q1 FY2015CQ3 2014 | Sep 30, 2014 | $2.12M | – |
| Q4 FY2014CQ2 2014 | Jun 30, 2014 | $830.59K | – |
| Q3 FY2014CQ1 2014 | Mar 31, 2014 | $966.34K | – |
See a number that looks wrong?